منابع مشابه
The future of adjuvant therapy for renal cell carcinoma
There is a need for effective adjuvant treatment in renal cell carcinoma (RCC). Significant proportions of patients remain at high risk of recurrence after surgery, particularly those with stage III disease. Two main scoring systems are available for predicting progression after surgery: the UCLA integrated scoring system and the Mayo Clinic stage, size, grade and necrosis nomogram (also know...
متن کاملAdjuvant Therapy in Renal Cell Carcinoma—Past, Present, and Future☆
To date, no effective adjuvant treatment for renal cell carcinoma (RCC) has been described, but research in this area is important since the 5-year relapse rate for intermediate- and high-risk early-stage RCC is 30%-40%. Metastatic RCC can be treated successfully with immune therapy and targeted therapy. Adjuvant trials with immune therapy have been conducted, but they reported no benefit in di...
متن کاملRenal Preservation Therapy for Renal Cell Carcinoma
Renal preservation therapy has been a promising concept for the treatment of localized renal cell carcinoma (RCC) for 20 years. Nowadays partial nephrectomy (PN) is well accepted to treat the localized RCC and the oncological control is proved to be the same as the radical nephrectomy (RN). Under the result of well oncological control, minimal invasive method gains more popularity than the open...
متن کاملSystemic adjuvant therapies in renal cell carcinoma
Renal cell carcinoma (RCC) is one of the ten most frequent solid tumors worldwide. Recent innovations in the treatment of metastatic disease have led to new therapeutic approaches being investigated in the adjuvant setting. Observation is the only current standard of care after radical nephrectomy, although there is evidence of efficacy of adjuvant use of vaccine among all the strategies used. ...
متن کاملUpdated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma.
The European Association of Urology Renal Cell Carcinoma (RCC) guidelines panel updated their recommendation on adjuvant therapy in unfavourable, clinically nonmetastatic RCC following the recently reported results of a second randomised controlled phase 3 trial comparing 1-yr sunitinib to placebo for high-risk RCC after nephrectomy (S-TRAC). On the basis of conflicting results from the two ava...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Cancer Metastasis and Treatment
سال: 2021
ISSN: ['2394-4722', '2454-2857']
DOI: https://doi.org/10.20517/2394-4722.2021.64